Humoral Immune Responses to HIV in the Mucosal Secretions and Sera of HIV-Infected Women

American Journal of Reproductive Immunology

Volumn 71, Issue 6, 2014, Pages 600-607

  Mestecky, Jiri ^a,b   Wei, Qing ^a   Alexander, Rashada ^a,c   Raska, Milan ^a,d   Novak, Jan ^a   Moldoveanu, Zina ^a  

^a University of Alabama at Birmingham   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Antibody responses; Human immunodeficiency virus; Mucosal immunity; Secretory IgA and IgG

Indexed keywords

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY DEPENDENT CELL MEDIATED VIRAL INHIBITION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CHEMOLUMINESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOCRINE SECRETION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; IMMUNIZATION; INTESTINE MUCOSA; MUCOSAL IMMUNITY; PRIORITY JOURNAL; RECTUM; SERUM; VAGINAL LAVAGE; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LOAD; VIRUS NEUTRALIZATION; WESTERN BLOTTING; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUCOSA; SECRETION (PROCESS); VIROLOGY;

ANTIBODIES, NEUTRALIZING; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MUCOUS MEMBRANE; VAGINAL DOUCHING;

EID: 84900826761     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12203     Document Type: Article

References (69)

1. Mestecky J: Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract as compared to other mucosal sites. J Reprod Immunol 2007; 73:86-97.
2. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC: Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009; 83:196-200.
3. Mestecky J, Raska M, Alexander RC, Moldoveanu Z: Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design. J Reprod Immunol 2010; 85:81-85.
4. Wira C, Fahley J: A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22:1909-1917.
5. Jackson S, Mestecky J, Moldoveanu Z, Spearman P: Appendix I: collection and processing of human mucosal secretions. In Mucosal Immunology, 3rd edn. J Mestecky, ME Lamm, L Mayer, W Strober, J Bienenstock, JR McGhee, L Mayer (eds). Amsterdam, The Netherlands, Elsevier Academic Press, 2005, pp 1647-1659.
6. Kutteh WH, Mestecky J, Wira CR: Mucosal immunity in the human female reproductive tract. In Mucosal Immunology, J Mestecky, ME Lamm, L Mayer, W Strober, J Bienenstock, JR McGhee, L Mayer (eds). Amsterdam, The Netherlands, Elsevier Academic Press, 2005, pp 1631-1646.
7. Kutteh WH, Prince SJ, Hammonds KR, Kutteh CC, Mestecky J: Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol 1996; 104:538-542.
8. Wright PF, Kozlowski PA, Rybczyk GK, Goepfert P, Staats HF, VanCott TC, Trabottoni D, Sannella E, Mestecky J: Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 2002; 18:1291-1300.
9. Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, Moldoveanu Z, Alexander RC, Kulhavy R, Pastori C, Maboko L, Riedner G, Zhu Y, Wrinn T, Hoelscher M: Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 2011; 27:469-486.
10. Jackson S, Prince S, Kulhavy R, Mestecky J: False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV-1 antigens. AIDS Res Hum Retroviruses 2000; 16:595-602.
11. Moldoveanu Z, Mestecky J: Mucosal antibody responses to HIV. In HIV Protocols, 2nd edn. VR Prasad, GV Kalpana (eds). New York, Humana Press / Springer Science, Methods Mol Biol 2009; 48: pp333-345.
12. Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince S, Sabbaj S, Mulligan MJ, Goepfert PA: Paucity of antigen-specific IgA responses in sera and external secretions of HIV-1-infected individuals. AIDS Res Hum Retroviruses 2004; 20:972-988.
13. Mohamed OA, Ashley R, Goldstein A, McElrath J, Dalessio J, Corey L: Detection of rectal antibodies to HIV-1 by a sensitive chemiluminescent western blot immunodetection method. J Acquir Immune Defic Syndr 1994; 7:375-380.
14. Wei Q, Moldoveanu Z, Huang WQ, Alexander RC, Goepfert PA, Mestecky J: Comparative evaluation of HIV-1 neutralization in external secretions and sera of HIV-1-infected women. Open AIDS J 2012; 6:293-302.
15. Mestecky J, Alexander RC, Wei Q, Moldoveanu Z: Methods of evaluation of humoral immune responses in human genital tract secretions. Am J Reprod Immunol 2011; 65:361-367.
16. Tamaras GD, Haynes BF: HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS 2009; 4:373-379.
17. Overbaugh J, Morris L: The antibody response against HIV-1. In Cold Spring Harbor Perspectives In Medicine, FD Bushman, GJ Nabel, R Swanstrom (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2012, pp 1-19.
18. Alexander R, Mestecky J: Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr HIV Res 2007; 5:588-593.
19. Kwong PD, Mascola JR, Nabel GJ: Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. In Cold Spring Harbor Perspectives in Medicine, FD Bushman, GJ Nabel, R Swanstrom (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2011, pp 1-17.
20. Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S: Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol 2011; 85:4927-4936.
21. Brombin C, Diomede L, Tudor D, Drillet AS, Pastori C, Poli E, Riva A, Uberti-Foppa C, Galli M, Di Serio C, Bomsel M, Lopalco L: A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients. PLoS ONE 2013; 8:1-13.
22. Mcneely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor:a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456-464.
23. Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM: Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis 1997; 3:64-69.
24. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, Challacombe SJ: Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006; 13:1111-1118.
25. Orsi N: The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 2004; 17:189-196.
26. Raska M, Novak J: Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection. Arch Immunol Ther Exp 2010; 58:191-208.
27. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659.
28. Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, Shaw GM: Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988; 334:440-444.
29. Keele BF, Giorgi EE, Salazar-Gonzalez F, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, We X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7557.
30. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Oshenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-1289.
31. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
32. Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, Moldoveanu Z, Elliott MC, Wilson L, Brown R, Jancova D, Barnes S, Vrbkova J, Tomana M, Smith PD, Mestecky J, Renfrow MB, Novak J: Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 2010; 285:20860-20869.
33. Amin MN, McLellan JS, Huang W, Orwenyo J, Burton DR, Koff WC, Kwong PD, Wang LX: Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat Chem Biol 2013; 9:521-526.
34. Berneman A, Belec L, Fischetti VA, Bouvet JP: The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infect Immun 1998; 66:4163-4168.
35. Mestecky J, Moldovenu Z, Russell MW: Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol 2005; 53:208-214.
36. Russell MW, Mestecky J: Humoral immune responses to microbial infections in the genital tract. Microbes Infect 2002; 4:667-677.
37. Mestecky J: The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987; 7:265-276.
38. Hur EM, Patel SN, Shimizu S, Rao DS, Gnanapragasam PNP, Sung An D, Yang L, Baltimore D: Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012; 120:4571-4582.
39. Kozlowski PA, Jackson S: Serum IgA subclasses and molecular forms in HIV infection: selective increase in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. AIDS Res Hum Retroviruses 1992; 8:1773-1780.
40. Murphy BR: Mucosal immunity to viruses. In Mucosal Immunology, 3rd edn. J Mestecky, ME Lamm, W Strober, J Bienenstock, JR McGhee, L Mayer (eds). Amsterdam, The Netherlands, Elsevier Academic Press, 2005, pp 799-813.
41. Holmgren J, Svennerholm A-M: Mucosal immunity to bacteria. In Mucosal Immunology, 3rd edn. J Mestecky, ME Lamm, W Strober, J Bienenstock, JR McGhee, L Mayer (eds). Amsterdam, The Netherlands, Elsevier Academic Press, 2005, pp 783-798.
42. Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E, Grouin JM, Sicard D, Blondeau C: Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. J Immunol Methods 1999; 222:111-124.
43. Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E, Grouin JM, Sicard D, Bloudeau C: Comparison of antibodies in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 1999; 15:1365-1376.
44. Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E, Gouin E, Sicard D, Blondeau C: IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 2000; 6:583-594.
45. Chaoul N, Burelout C, Peruchon S, van Buu BN, Laurent P, Proust A, Raphael M, Garraud O, Le Grand R, Prevot S, Richard Y: Default in plasma and intestinal IgA responses during acute infection by simian immunodeficiency virus. Retrovirology 2012; 9:43.
46. Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C: Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals. AIDS 1995; 9:695-700.
47. Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C: Induction and expression of intestinal humoral immunity in HIV-infected individuals: prospects for vaccination against secondary enteric infections. Pathobiology 1998; 66:176-182.
48. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP: Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108:11181-11186.
49. Mascola JR: Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002; 20:1922-1925.
50. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343-346.
51. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
52. Walker LM, Burton DR: Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010; 22:1-9.
53. Mascola JR: Define the protective antibody response for HIV-1. Curr Mol Med 2003; 3:209-216.
54. Lamm ME: Protection of mucosal epithelia by IgA: intracellular neutralization and excretion of antigens. In Mucosal Immune Defense: Immunoglobuin A, CS Kaetzel (ed). New York, Springer Science+Business Media, LLC, 2007, pp 173-182.
55. Mantis NJ, Palaia J, Hessell AJ, Mehta S, Zhu Z, Corthesy B, Neutra MR, Burton DR, Janoff EN: Inhibitionof HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 2007; 179:3144-3152.
56. Wright A, Lamm ME, Huang YT: Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol 2008; 82:11526-11535.
57. Huang YT, Wright A, Gao X, Kulick L, Yan H, Lamm M: Intraepithelial cell neutralization of HIV-1 replication. J Immunol 2005; 174:4828-4835.
58. Dembert T, Robert-Guroff M: Mucosal immunity and protection against HIV / SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009; 28:20-48.
59. Woof JM, Mestecky J: Mucosal Immunoglobulins. Immunol Rev 2005; 206:64-82.
60. Mestecky J, Russell MW: Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces. Immunol Lett 2009; 124:57-62.
61. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao H-X, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, deSouza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH: Immune-correlates analysis of an HIV-1 vaccine efficacy trail. N Engl J Med 2012; 366:1275-1286.
62. Russell MW, Kilian M: Biological activities of IgA. In Mucosal Immunology, 3rd edn. J Mestecky, ME Lamm, W Strober, J Bienenstock, JR McGhee, L Mayer (eds). Amsterdam, The Netherlands, Elsevier Academic Press, 2005, pp 267-289.
63. Xu W, Santini PA, Sullivan JS, He B, Shan M, Ball SC, Dyer WB, Ketas TJ, Chadburn A, Cohen-Gould L, Knowles DM, Chiu A, Sanders RW, Chen K, Cerutti A: HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009; 10:1008-1017.
64. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A: Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7:302-310.
65. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X: Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 2011; 108:4388-4393.
66. Crowley-Nowick PA, Bell M, Edwards RP, McCallister D, Gore H, Kanbour-Shakir A, Mestecky J, Partridge EE: Normal uterine cervix: characterization of isolated lymphocyte phenotypes and immunoglobulin secretion. Am J Reprod Immunol 1995; 34:214-247.
67. Gupta S, Becerra JC, Gach JS, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping L-H, Corti D, Moldt B, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN: The neonatal Fc receptor (FcRn) enhances transcytosis of IgG-bound HIV-1 across intact epithelial monolayers. PLoS Pathog 2013; 9:e1003776.
68. Kibe T: Glycosylation and placental transport of immunologlobulin G. J Clin Biochem Nutr 1996; 21:57-63.
69. Forthal DN, Gash JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H: Fc-glycosylation influences receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010; 185:6876-6882.